GlobeImmune Company Profile (NASDAQ:GBIM)

About GlobeImmune

GlobeImmune logoGlobeImmune, Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company's segment is the business of developing and commercializing various biopharmaceutical products. The Company's infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company's oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GBIM
  • CUSIP:
Key Metrics:
  • Previous Close: $0.18
  • 50 Day Moving Average: $0.29
  • 200 Day Moving Average: $0.70
  • 52-Week Range: $0.11 - $3.38
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.04M
  • Outstanding Shares: 5,751,000
  • Beta: 2.8
Additional Links:
Companies Related to GlobeImmune:

Analyst Ratings

Consensus Ratings for GlobeImmune (NASDAQ:GBIM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for GlobeImmune (NASDAQ:GBIM)
No equities research coverage for this company has been tracked by


Earnings History for GlobeImmune (NASDAQ:GBIM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2016Q1($0.27)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlobeImmune (NASDAQ:GBIM)
No earnings estimates for this company have been tracked by


Dividend History for GlobeImmune (NASDAQ:GBIM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for GlobeImmune (NASDAQ:GBIM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/18/2016Augustine LawlorDirectorSell11,000$1.55$17,050.00View SEC Filing  
3/17/2016Daniel J MitchellDirectorSell21,600$1.66$35,856.00View SEC Filing  
3/15/2016Daniel J MitchellDirectorSell130,269$2.26$294,407.94View SEC Filing  
3/11/2016Augustine LawlorDirectorSell16,500$1.60$26,400.00View SEC Filing  
3/10/2016Daniel J MitchellDirectorSell16,400$1.17$19,188.00View SEC Filing  
3/8/2016Augustine LawlorDirectorSell15,010$1.05$15,760.50View SEC Filing  
3/7/2016Daniel J MitchellDirectorSell11,920$1.05$12,516.00View SEC Filing  
3/3/2016Augustine LawlorDirectorSell15,990$1.11$17,748.90View SEC Filing  
3/2/2016Daniel J MitchellDirectorSell17,422$1.02$17,770.44View SEC Filing  
3/1/2016Daniel J MitchellDirectorSell8,799$0.96$8,447.04View SEC Filing  
2/29/2016Augustine LawlorDirectorSell15,000$0.98$14,700.00View SEC Filing  
2/26/2016Daniel J MitchellDirectorSell12,501$1.03$12,876.03View SEC Filing  
2/24/2016Augustine LawlorDirectorSell15,000$1.33$19,950.00View SEC Filing  
2/23/2016Daniel J MitchellDirectorSell22,858$1.42$32,458.36View SEC Filing  
2/22/2016Augustine LawlorDirectorSell5,000$1.43$7,150.00View SEC Filing  
2/19/2016Ventures Vii Lp HealthcareInsiderSell15,000$1.44$21,600.00View SEC Filing  
2/18/2016Daniel J MitchellDirectorSell21,897$1.45$31,750.65View SEC Filing  
2/16/2016Ventures Vii Lp HealthcareMajor ShareholderSell15,000$1.61$24,150.00View SEC Filing  
2/12/2016Daniel J MitchellDirectorSell3,645$1.75$6,378.75View SEC Filing  
2/9/2016Daniel J MitchellDirectorSell7,300$2.05$14,965.00View SEC Filing  
7/8/2014Celgene International IncMajor ShareholderBuy200,000$10.00$2,000,000.00View SEC Filing  
7/8/2014S. Edward TorresDirectorBuy85,000$10.00$850,000.00View SEC Filing  
7/8/2014Timothy C Rodell JrCEOBuy5,000$10.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for GlobeImmune (NASDAQ:GBIM)
News IconGlobeimmune Inc GBIM Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:GBIM) - February 23 at 5:22 PM
News IconGlobeimmune Inc GBIM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:GBIM) - January 13 at 11:33 PM logoWhat’s Next At GlobeImmune Inc (OTCMKTS:GBIM)? (NASDAQ:GBIM) - November 22 at 4:57 PM logoCelgene : PharmAkea Extends Collaboration with Celgene Corporation (NASDAQ:GBIM) - November 22 at 4:57 PM
News IconWhat’s Next At GlobeImmune Inc (GBIM)? (NASDAQ:GBIM) - November 21 at 1:44 PM logoTENX Awaits Data In Jan, GBIM Hit Hard, FDA Says No To SPPI (NASDAQ:GBIM) - November 21 at 10:15 AM logoGilead CEO Resigns, Dumps GlobeImmune Pact (GILD) (NASDAQ:GBIM) - November 18 at 4:41 PM logo3:55 am Globelmmune provides corporate update; CEO resigns, Gilead (GILD (NASDAQ:GBIM) - November 18 at 8:01 AM logoGlobeImmune Announces Updates (NASDAQ:GBIM) - November 17 at 10:22 PM logoBRIEF-GlobeImmune announces updates (NASDAQ:GBIM) - November 17 at 6:17 PM
News IconLouisville's GlobeImmune, struggling and down to 2 employees, delists from Nasdaq (NASDAQ:GBIM) - July 8 at 5:02 AM
News IconGlobeImmune (GBIM) to Delist from the Nasdaq After Weighing Options (NASDAQ:GBIM) - July 8 at 5:02 AM logoMid-Day Market Update: U.S. Stocks Turn Positive; Nortek Shares Surge Following Acquisition News (NASDAQ:GBIM) - July 6 at 5:18 PM logoAfter-Hours Stock Movers 07/05: (EGLE) (MDVN) (BIIB) Higher; (GBIM) (VTR) (TSLA) Lower (more...) (NASDAQ:GBIM) - July 6 at 5:18 PM
News IconGlobeImmune shares going off Nasdaq exchange: Stock dives Wednesday (NASDAQ:GBIM) - July 6 at 5:18 PM logoWhy Tesla, Apple, Alibaba, and Two Other Stocks Are Trending Today (NASDAQ:GBIM) - July 6 at 10:49 AM logoGLOBEIMMUNE INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T (NASDAQ:GBIM) - July 5 at 4:44 PM logoGlobeImmune Announces Delisting and Deregistration of Common Stock (NASDAQ:GBIM) - July 5 at 4:30 PM
News IconGlobeImmune Inc (NASDAQ:GBIM): We Bought The Stock At $1.93 and Sold at $3.30, Amazing Quick profit (NASDAQ:GBIM) - June 22 at 9:49 AM logoIs this Colorado biotech a takeover target? (NASDAQ:GBIM) - June 20 at 11:22 AM
News IconGlobeImmune Inc (NASDAQ:GBIM): That’s Why Profit Taking Is Must, Reached Our Target on Friday, Now Down (NASDAQ:GBIM) - June 20 at 11:22 AM
News IconGlobeImmune Inc (NASDAQ:GBIM): How Did Our members Trade The Stock? Massive Win In A Single Day (NASDAQ:GBIM) - June 20 at 11:22 AM
News IconGlobeImmune Inc (NASDAQ:GBIM): It’s All About Chart For The Momentum Trade (NASDAQ:GBIM) - June 19 at 9:28 AM
News IconGlobeImmune Inc (NASDAQ:GBIM): Just Reached Our Target of $3.30 In 24 Hours – Made 70% (NASDAQ:GBIM) - June 18 at 9:39 AM logoThese Four Companies Are a Must for Your Watchlist, in June (NASDAQ:GBIM) - June 17 at 5:02 PM
News IconGlobeImmune Inc (NASDAQ:GBIM) And EXACT Sciences Corporation (NASDAQ:EXAS) Are Big Winners Of This Week (NASDAQ:GBIM) - June 17 at 5:02 PM logoU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.53% (NASDAQ:GBIM) - June 16 at 5:09 PM logoWhy Korn/Ferry, AMD, Wells Fargo & Two Other Stocks Are in Spotlight Today (NASDAQ:GBIM) - June 16 at 1:42 PM logoMarkets Rally Belatedly To ECB Bazooka (GBIM) (NASDAQ:GBIM) - March 11 at 11:47 AM
News IconGlobeImmune’s CEO cuts own hours, salary to preserve capital (NASDAQ:GBIM) - February 26 at 10:20 AM logoGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:GBIM) - February 23 at 4:12 PM logoGLOBEIMMUNE INC Financials (NASDAQ:GBIM) - December 8 at 1:18 PM logoGLOBEIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:GBIM) - November 13 at 9:12 AM logoGlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights (NASDAQ:GBIM) - November 13 at 6:30 AM logoGLOBEIMMUNE INC Files SEC form 10-Q, Quarterly Report (NASDAQ:GBIM) - November 13 at 6:15 AM logoGlobeImmune, Inc. – Value Analysis (NASDAQ:GBIM) : November 3, 2015 (NASDAQ:GBIM) - November 3 at 12:08 PM logoGlobeImmune, Inc. Earnings Q2, 2015 (NASDAQ:GBIM) - September 30 at 11:04 AM logoGlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights (NASDAQ:GBIM) - August 14 at 6:30 AM logoGlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options (NASDAQ:GBIM) - August 13 at 6:30 AM logoGLOBEIMMUNE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:GBIM) - August 4 at 4:29 PM logoGLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:GBIM) - July 17 at 4:31 PM logoGLOBEIMMUNE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:GBIM) - July 13 at 4:12 PM logoCan Hepatitis B Be A Blockbuster Bug? (NASDAQ:GBIM) - July 1 at 8:02 AM


What is GlobeImmune's stock symbol?

GlobeImmune trades on the NASDAQ under the ticker symbol "GBIM."

When will GlobeImmune announce their earnings?

GlobeImmune is scheduled to release their next quarterly earnings announcement on Monday, August, 15th 2016.

How do I buy GlobeImmune stock?

Shares of GlobeImmune can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GlobeImmune stock cost?

One share of GlobeImmune stock can currently be purchased for approximately $0.18.

GlobeImmune (NASDAQ:GBIM) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for GlobeImmune (NASDAQ:GBIM)

Earnings History Chart

Earnings by Quarter for GlobeImmune (NASDAQ:GBIM)

Dividend History Chart

Dividend Payments by Quarter for GlobeImmune (NASDAQ:GBIM)

Last Updated on 2/25/2017 by Staff